EURONEXT-BRU$ARGX
Argenx Se · Q2 2026 earnings
Q2 2026 earnings · · Investor relations
Briefing
Argenx Se reported strong Q2 2026 results with $1.5 billion in global product net sales, up 60% year-over-year.
Argenx SE announced its half-year 2026 financial results on July 23, 2026, highlighting robust Q2 performance driven by VYVGART sales growth. The company achieved $1.516 billion in product net sales for the quarter, leading to an operating profit of $494 million and net profit of $472 million. Diluted EPS reached $7.32, significantly ahead of prior year.
- Global product net sales of $1.516 billion, +60% YoY and +17% QoQ.
- Operating profit of $494 million and net profit of $472 million for the quarter.
- Diluted EPS of $7.32, compared to $3.74 in Q2 2025.
- Successful U.S. launch expansion of VYVGART to all gMG serotypes.
Headline financials
Revenue & EPS history
Argenx · Revenue · Quarterly
$1.52B
Revenue by segment
Argenx · $1.52B total across 1 segment · Q2 2026
- VYVGART$1.52B—100.0%
Forward guidance
Company remains on track with multiple registrational study readouts expected in H2 2026 and beyond.
Tailwinds
- ALKIVIA myositis readout in 3Q26
- EMPASSION MMN readout in 4Q26
- Pipeline expansion with multiple new indications and molecules
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+0.3%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+3.8%
Avg return
30 days after
56%
18 / 32 earnings
Positive
+11.2%
Q4 2017
Best reaction
-9.1%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q4 2026 | +1.7% | -8.1% | -19.0% | |
| Q1 2025 | -9.1% | -12.9% | -5.9% | |
| Q4 2024 | +0.3% | -0.3% | -5.4% | |
| Q3 2024 | +8.0% | +9.2% | +11.8% | |
| Q2 2024 | +6.5% | +9.7% | +11.3% | |
| Q1 2024 | -3.0% | -7.8% | -2.7% | |
| Q3 2023 | +6.6% | +7.7% | -2.9% | |
| Q2 2023 | -1.1% | -3.3% | -2.7% | |
| Q1 2023 | +3.0% | +2.4% | +0.9% | |
| Q4 2022 | -5.9% | -8.1% | +1.0% | |
| Q3 2022 | +1.4% | -1.1% | -2.6% | |
| Q2 2022 | +1.8% | -0.0% | +7.3% | |
| Q1 2022 | +8.0% | +2.2% | +8.0% | |
| Q4 2021 | -8.7% | -9.5% | +11.7% | |
| Q3 2021 | +8.0% | +14.8% | -1.2% | |
| Q2 2021 | -1.0% | +1.3% | +9.5% | |
| Q1 2021 | +6.3% | +0.8% | +20.4% | |
| Q4 2020 | -8.4% | -0.3% | -10.7% | |
| Q3 2020 | -2.5% | +0.8% | +4.9% | |
| Q2 2020 | -7.8% | -7.2% | -8.2% | |
| Q1 2020 | +5.7% | +10.0% | +45.0% | |
| Q4 2019 | -6.1% | -2.1% | -13.2% | |
| Q3 2019 | +0.4% | +4.9% | +24.8% | |
| Q2 2019 | +1.5% | -4.4% | -6.4% | |
| Q1 2019 | -3.2% | -6.2% | -3.0% | |
| Q4 2018 | +0.4% | -2.3% | -6.9% | |
| Q3 2018 | -5.0% | -3.9% | +17.2% | |
| Q2 2018 | -1.2% | -0.9% | +1.8% | |
| Q1 2018 | +2.6% | +3.5% | +13.2% | |
| Q4 2017 | +11.2% | +7.7% | +5.0% | |
| Q3 2017 | +1.1% | +0.7% | +13.4% | |
| Q2 2017 | -0.6% | -0.6% | +4.2% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro